Constellation Pharmaceuticals Inc (NASDAQ:CNST) Insider Karen Valentine Sells 4,473 Shares

Constellation Pharmaceuticals Inc (NASDAQ:CNST) insider Karen Valentine sold 4,473 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.07, for a total value of $156,868.11. Following the completion of the transaction, the insider now directly owns 1,500 shares of the company’s stock, valued at $52,605. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Karen Valentine also recently made the following trade(s):

  • On Tuesday, February 11th, Karen Valentine sold 8,550 shares of Constellation Pharmaceuticals stock. The stock was sold at an average price of $35.03, for a total value of $299,506.50.

NASDAQ CNST opened at $36.06 on Friday. Constellation Pharmaceuticals Inc has a fifty-two week low of $6.01 and a fifty-two week high of $59.49. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -11.48 and a beta of 6.93. The business has a fifty day moving average of $38.67 and a 200-day moving average of $24.33. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.81.

A number of equities analysts have recently weighed in on CNST shares. Jefferies Financial Group reissued a “buy” rating and issued a $40.00 price target (up from $17.00) on shares of Constellation Pharmaceuticals in a report on Thursday, November 7th. Robert W. Baird reissued an “outperform” rating and issued a $65.00 price target (up from $35.00) on shares of Constellation Pharmaceuticals in a report on Tuesday, December 10th. Zacks Investment Research cut Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. BMO Capital Markets cut Constellation Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $43.00 to $42.00 in a report on Thursday, January 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Constellation Pharmaceuticals in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $44.09.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Constellation Pharmaceuticals in the fourth quarter valued at $36,000. Victory Capital Management Inc. grew its position in shares of Constellation Pharmaceuticals by 43.4% in the fourth quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock valued at $73,000 after purchasing an additional 666 shares during the period. Bank of Montreal Can grew its position in shares of Constellation Pharmaceuticals by 43.0% in the fourth quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock valued at $91,000 after purchasing an additional 582 shares during the period. Citigroup Inc. grew its position in shares of Constellation Pharmaceuticals by 267.6% in the fourth quarter. Citigroup Inc. now owns 3,099 shares of the company’s stock valued at $146,000 after purchasing an additional 2,256 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Constellation Pharmaceuticals in the fourth quarter valued at $195,000. 49.91% of the stock is owned by institutional investors.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Article: Percentage Decliners

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.